FDA-cleared profile

Methinks NCCT Stroke

Methinks Software S.L. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Clinical role
Triage and notification support
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The preview is not diagnostic, a negative result does not rule out LVO, and the device does not replace CTA, standard care, or full clinical evaluation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Adult non-contrast head CT in DICOM format; the device evaluates suspected intracranial hemorrhage and ICA/MCA-M1/MCA-M2 LVO findings. CTA remains standard care for LVO evaluation.
  • Who uses it?Intended users: Trained physicians and stroke clinicians responsible for acute head CT review and patient evaluation
  • What does the software produce?Output: PACS and/or notification-client alerts for suspected intracranial hemorrhage or suspected LVO; a preview may be shown for information, while clinicians must review the original diagnostic images and full patient context.
  • What is its most important limitation?Key limitation: The preview is not diagnostic, a negative result does not rule out LVO, and the device does not replace CTA, standard care, or full clinical evaluation.

Clinical takeaway. Clinical role: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Evidence takeaway. Evidence from the reviewed source record: Retrospective blinded multicenter multinational validation included separate ICH and LVO cohorts; the FDA packet reports 358 ICH cases and 335 LVO cases.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Triage and notification support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Adult non-contrast head CT in DICOM format; the device evaluates suspected intracranial hemorrhage and ICA/MCA-M1/MCA-M2 LVO findings. CTA remains standard care for LVO evaluation.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
PACS and/or notification-client alerts for suspected intracranial hemorrhage or suspected LVO; a preview may be shown for information, while clinicians must review the original diagnostic images and full patient context.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult acute-stroke hospital workflow
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Trained physicians and stroke clinicians responsible for acute head CT review and patient evaluation
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The preview is not diagnostic, a negative result does not rule out LVO, and the device does not replace CTA, standard care, or full clinical evaluation.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Retrospective blinded multicenter multinational validation included separate ICH and LVO cohorts; the FDA packet reports 358 ICH cases and 335 LVO cases.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective blinded multicenter multinational validation included separate ICH and LVO cohorts; the FDA packet reports 358 ICH cases and 335 LVO cases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
ICH sensitivity 94.7% (95% CI 89.3%-97.8%); LVO sensitivity 76.4% (95% CI 67.3%-83.9%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported specificity
ICH specificity 99.5% (95% CI 97.5%-99.9%); LVO specificity 91.1% (95% CI 86.6%-94.5%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

ICH sensitivity

94.7 percent

  • EndpointIntracranial hemorrhage detection
  • Population358 NCCT cases; 132 positive and 226 negative
  • Tested versionMethinks NCCT Stroke submitted in K250685; build not stated

ICH specificity

99.5 percent

  • EndpointIntracranial hemorrhage detection
  • Population358 NCCT cases; 132 positive and 226 negative
  • Tested versionMethinks NCCT Stroke submitted in K250685; build not stated

LVO sensitivity

76.4 percent

  • EndpointLVO detection on NCCT
  • Population335 NCCT cases; 110 positive and 225 negative
  • Tested versionMethinks NCCT Stroke submitted in K250685; build not stated

LVO specificity

91.1 percent

  • EndpointLVO detection on NCCT
  • Population335 NCCT cases; 110 positive and 225 negative
  • Tested versionMethinks NCCT Stroke submitted in K250685; build not stated

Methinks NCCT Stroke multicenter ICH and LVO validation

  • DesignRetrospective blinded multicenter multinational standalone performance study
  • PopulationSeparate NCCT cohorts: 358 ICH cases and 335 LVO cases
  • Scopeexact submission
  • Tested versionMethinks NCCT Stroke submitted in K250685; build not stated
  • Samplen=693
  • IndependenceIndependence not established

K250685

The FDA reports separate evaluation cohorts and notification timing of about 1.4 minutes for each task; this does not establish independent investigators or sponsorship. Reader-study results are kept distinct from standalone cohort metrics.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult non-contrast head CT in DICOM format; the device evaluates suspected intracranial hemorrhage and ICA/MCA-M1/MCA-M2 LVO findings. CTA remains standard care for LVO evaluation.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K250685: Methinks NCCT Stroke

  2. Routing

    Source context, not route validation: The FDA submission describes DICOM NCCT ingestion, PACS delivery, and notification clients for parallel triage; local routing, interfaces, and escalation policy require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K250685: Methinks NCCT Stroke

  3. AI processing

    Source context, not route validation: Cloud-based deployment is explicitly described in the exact-submission source; hosting region, data flow, retention, and current commercial configuration require vendor confirmation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) K250685: Methinks NCCT Stroke

  4. Returned objects

    Source context, not route validation: PACS and/or notification-client alerts for suspected intracranial hemorrhage or suspected LVO; a preview may be shown for information, while clinicians must review the original diagnostic images and full patient context.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K250685: Methinks NCCT Stroke

  5. Viewer/worklist/report

    Unresolved route: PACS and/or notification-client alerts for suspected intracranial hemorrhage or suspected LVO; a preview may be shown for information, while clinicians must review the original diagnostic images and full patient context.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K250685: Methinks NCCT Stroke

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-based deployment is explicitly described in the exact-submission source; hosting region, data flow, retention, and current commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
The FDA submission describes DICOM NCCT ingestion, PACS delivery, and notification clients for parallel triage; local routing, interfaces, and escalation policy require confirmation.
  • Exact FDA submission
  • Checked 2026-09-06
Security
The FDA submission describes a risk-based cybersecurity process including SBOM, third-party penetration testing, authentication/authorization, logging, cryptography, monitoring, and recovery controls; current attestation and scope were not established.
  • Exact FDA submission
  • Checked 2026-09-06

Submission-described controls are not treated as a current independent security certification.

Cloud NCCT triage workflow

The exact submission describes cloud-based DICOM NCCT processing with PACS and notification-client alerts for ICH and LVO triage.

exact submission · checked 2026-09-06

Methinks family coordination workflow

Methinks' official platform page describes NCCT/CTA stroke workflows with AI alerts, team coordination, video communication, image viewing, and Microsoft Teams integration; the current configuration of K250685 requires confirmation.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250685
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-06-16
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Methinks Stroke reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K250685: Methinks NCCT Stroke

    U.S. Food and Drug Administration - Published 2025-06-16 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudies, security

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Methinks NCCT Stroke model card (K250685)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, deployment, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Methinks official stroke platform page

    Methinks - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

Research history

  1. K250685 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K240353

Hyper Insight - ICH

SK Inc.

Authorized purpose: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2024-07-01

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history